- Home
- TTGT vs SIGA Comparison
TTGT vs SIGA Comparison
Compare TTGT & SIGA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TTGT | SIGA |
|---|---|---|
| Founded | 1999 | 1995 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 344.2M | 341.0M |
| IPO Year | 2024 | 2016 |
Fundamental Metrics
Financial Performance| Metric | TTGT | SIGA |
|---|---|---|
| Price | $5.64 | $4.53 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 4 | 0 |
| Target Price | ★ $10.75 | N/A |
| AVG Volume (30 Days) | 470.3K | ★ 651.7K |
| Earning Date | 05-07-2026 | 05-05-2026 |
| Dividend Yield | N/A | ★ 13.07% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ 0.32 |
| Revenue | N/A | N/A |
| Revenue This Year | $4.45 | N/A |
| Revenue Next Year | $2.75 | $224.81 |
| P/E Ratio | ★ N/A | $14.33 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.41 | $4.29 |
| 52 Week High | $9.00 | $9.62 |
Technical Indicators
Market Signals| Indicator | TTGT | SIGA |
|---|---|---|
| Relative Strength Index (RSI) | 68.51 | 39.09 |
| Support Level | $5.44 | $4.29 |
| Resistance Level | $5.88 | $4.80 |
| Average True Range (ATR) | 0.33 | 0.14 |
| MACD | 0.15 | 0.04 |
| Stochastic Oscillator | 86.57 | 44.12 |
Price Performance
Historical ComparisonAbout TTGT TechTarget Inc.
TechTarget Inc is engaged in the business-to-business (B2B) accelerator, informing and influencing technology buyers and sellers. Through its B2B first-party data and an end-to-end portfolio of data-driven solutions, it services the full B2B product lifecycle for customers from, messaging, and content development to in-market activation via brand, demand generation, purchase intent data, and sales enablement from R&D to ROI.
About SIGA SIGA Technologies Inc.
SIGA Technologies Inc a commercial-stage pharmaceutical company. The Company sells its product, TPOX oral TPOXX, also known as tecovirimat, Tecovirimat-SIGA, or TEPOXX (tecovirimat) in certain international markets, to the U.S. Government and international governments (including government-affiliated entities). The Company operates in one single operating and reportable segment, which includes all activities related to the sale of the Company's Oral and IV TPOXX as well as research and development services.